Kessler Topaz Meltzer & Check, LLP: Investigation on Behalf of Stryker Corporation Shareholders

Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of purchasers of Stryker Corporation (NYSE:  SYK) between April 27, 2021 and April 5, 2022.

Stryker investors may receive additional information about the investigation by clicking the link "Submit Your Information" above.

Stryker is a medical technology company that operates through two segments: MedSurg and Neurotechnology and Orthopedics and Spine.

On April 6, 2022, Spruce Point Capital Management (Spruce Point) published a report alleging that Stryker has failed to disclose certain material facts to investors concerning its operations. Specifically, Spruce Point stated that it "Finds Evidence That Stryker Has Failed to Disclose Inventory Accounting Challenges and Made Various Changes to Accounting Policies Designed to Flatter Its Performance, Using Greater Non-GAAP Adjustments to Portray Margin Stability and Earnings Growth.” Additionally, the report indicated, among other things, that Stryker has concealed from investors that its true exposure to elective procedures adversely impacted by the COVID-19 pandemic was 50% of sales; that a critical ERP project to unify over 40 systems failed miserably; and that critical materials inventory continues to be hampered by supply chain challenges and inflationary pressures.

Following this news, the price of Stryker shares were down over 4% in early morning trading on April 6, 2022.

If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP:  James Maro, Esq. (484) 270-1453 or via e-mail at [email protected].